| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Other Events
As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determi... |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), ... |
| 23 Jun 2026 |
8-K: Other Events
As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) relating to its suit against Pfizer Inc... |
| 18 Jun 2026 |
8-K: Regulation FD Disclosure
Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research a... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 |
| 26 Mar 2026 |
8-K: Other Events
As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. s... |
| 12 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract... |
| 09 Feb 2026 |
8-K: Results of Operations and Financial Condition
Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) |
| 17 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models |
| 01 Oct 2025 |
8-K: Other Events
Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representativ... |
| 29 Sep 2025 |
8-K: Regulation FD Disclosure
Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results September 29, 2025 Exhibit 99.1 |
| 29 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults |
| 27 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 26, 2025, the Board of Directors of Enanta Pharmaceuticals, Inc. (the “Company”) designated Harry R. Trout, III, Vice President, Finance of the Company, as the Company’s interim principal financial officer and Kathleen (“Katie”... |
| 20 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
WATERTOWN, Mass.—August 20, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today tha... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 |
| 17 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract... |
| 10 Feb 2025 |
8-K: Results of Operations and Financial Condition
On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 |
Loading...